1-3 of 3
Willem JL Van Putten
Close
Sort by
Journal Articles

High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.

Gröschel Stefan, Sanne Lugthart, Richard Schlenk, Peter Valk, Karina Eiwen, Chantal Goudswaard, Willem JL Van Putten, Sabine Kayser, Leo Verdonck, Michael Lübbert, Gert Ossenkoppele, Ulrich Germing, Ingo Schmidt-Wolf, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Bob Löwenberg, Konstanze Döhner, Ruud Delwel
Journal: Blood
Blood (2009) 114 (22): 582.
https://doi.org/10.1182/blood.V114.22.582.582
Published: 2009
Journal Articles

Alemtuzumab-CHOP for Aggressive T Cell Lymphoma. A Phase II HOVON 69 Trial.

J.C. Kluin-Nelemans, MD, PhD, Marinus Van Marwijk Kooij, MD, PhD, P.J. Lugtenburg, MD, PhD, Pierre W Wijermans, Willem JL Van Putten, MSc, Gustaaf W van Imhoff, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1999.
https://doi.org/10.1182/blood.V112.11.1999.1999
Published: 2008
Journal Articles

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z S Rohatiner, MD, Gilles Andre Salles, MD, PhD, Jens Kuhlmann, Willem JL Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek
Journal: Blood
Blood (2008) 112 (11): 2002.
https://doi.org/10.1182/blood.V112.11.2002.2002
Published: 2008